Teva Company Profile

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has seven hundred and thirty-seven approved drugs.

There are one hundred US patents protecting TEVA drugs. There are fifty-three tentative approvals on TEVA drugs.

There are nine hundred and fourteen patent family members on TEVA drugs in forty-nine countries and one thousand and fifty-six supplementary protection certificates in eighteen countries.

Summary for Teva

International Patents:	914
US Patents:	100
Tradenames:	509
Ingredients:	444
NDAs:	737
Patent Litigation for Teva:	See patent lawsuits for Teva
PTAB Cases with Teva as petitioner:	See PTAB cases with Teva as petitioner

Drugs and US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	CHOLESTYRAMINE	cholestyramine	POWDER;ORAL	074347-002	May 28, 1998		DISCN	No	No
Teva Pharms	LINEZOLID	linezolid	SOLUTION;INTRAVENOUS	200222-001	Jun 27, 2012		DISCN	No	No
Teva	SILDENAFIL CITRATE	sildenafil citrate	TABLET;ORAL	077342-001	Mar 9, 2016	AB	RX	No	No

Expired US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	NORDETTE-28	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	018782-001	Jul 21, 1982	3,850,911
Teva Branded Pharm	QVAR 80	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-001	Sep 15, 2000	5,776,432
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-001	Jan 27, 2017	6,748,947

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	for Injection	3.5 mg/vial		2016-10-26
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	for Injection	100 mcg/vial and 500 mcg/vial		2015-04-14
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18
	Tablets	0.5 mg and 1 mg		2010-05-17
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Delayed-release Tablets	20 mg		2015-06-03
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	for Injection	200 mcg/vial		2015-05-01
	Tablets	1 mg/0.02 mg and 75 mg		2006-04-17
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10

Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for Teva Drugs

Country	Patent Number	Estimated Expiration
South Korea	101618936
China	102333566
European Patent Office	3701988

Supplementary Protection Certificates for Teva Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1255752	SPC/GB08/007	United Kingdom		PRODUCT NAME: SUNITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE L-MALATE SALT.; REGISTERED: UK EU/1/06/347/001 20060724; UK EU/1/06/347/002 20060724; UK EU/1/06/347/003 20060724
2487163	CA 2017 00003	Denmark		PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG ATAZANAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER ATAZANAVIRSULFAT; REG. NO/DATE: EU/1/15/1025/001-002 20150715
1261586	C300524	Netherlands		PRODUCT NAME: COMBINATIE VAN SAXAGLIPTINE EN METFORMINE, DESGEWENST IN DE VORM VAN FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN; NAT. REGISTRATION NO/DATE: EU/1/11/731/001-012 20111124; FIRST REGISTRATION:

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral